On Sept 11, 2023, XOMA Corporation Received $4.9M Commercial Payment From Genentech, Stemming From Sales Of Vabysmo During First 6 Months Of 2023
Portfolio Pulse from Benzinga Newsdesk
XOMA Corporation received a commercial payment of $4.9M from Genentech, which is derived from the sales of Vabysmo during the first half of 2023.
September 11, 2023 | 8:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
XOMA Corporation's revenue is boosted by a $4.9M payment from Genentech, resulting from H1 2023 sales of Vabysmo.
The news directly mentions XOMA Corporation receiving a significant commercial payment from Genentech. This payment, which is a result of the sales of Vabysmo, contributes to XOMA's revenue, potentially improving its financial performance and making it more attractive to investors. Therefore, this news is likely to have a positive impact on XOMA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100